Daxor Co. (NASDAQ:DXR) Sees Large Decline in Short Interest

Daxor Co. (NASDAQ:DXR) was the target of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 12,100 shares, a decrease of 8.3% from the January 15th total of 13,200 shares. Currently, 0.6% of the company’s shares are short sold. Based on an average daily volume of 16,500 shares, the short-interest ratio is currently 0.7 days.

Hedge Funds Weigh In On Daxor

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC grew its holdings in Daxor Co. (NASDAQ:DXR) by 34.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned about 0.30% of Daxor worth $126,000 at the end of the most recent reporting period. Institutional investors own 1.34% of the company’s stock.

Daxor Price Performance

DXR traded up $0.05 during mid-day trading on Monday, hitting $7.18. 3,233 shares of the stock were exchanged, compared to its average volume of 4,748. The firm’s fifty day moving average is $7.96 and its two-hundred day moving average is $8.62. Daxor has a 1-year low of $6.55 and a 1-year high of $10.00.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.